Inhibition of active-transport sodium-potassium-A.T.P.ase by myeloma protein.
Patients with multiple myeloma excrete immunoglobulin light chain (Bence-Jones protein) in the urine. Light chain accumulates in the nephron, and this may result in renal disease, which accounts for the death of between 1 in 4 and 1 in 7 patients with multiple myeloma. Myeloma light chain inhibits transport of paraaminohippurate in the kidney. Evidence is presented here that light chain affects renal transport by inhibiting the active-transport enzyme, ouabain-sensitive Na-K-A.T.P.ase. As a direct consequence, renal A.T.P. content and the maximum rate of gluconeogenesis from lactate are enhanced in the presence of light chain.
D000251:Adenosine Triphosphatases / Q000378:metabolism*; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001536:Bence Jones Protein / Q000378:metabolism* / Q000652:urine; D001693:Biological Transport, Active; D002462:Cell Membrane / Q000378:metabolism; D005943:Gluconeogenesis; D007147:Immunoglobulin Light Chains; D007684:Kidney Tubules / Q000473:pathology; D008297:Male; D009101:Multiple Myeloma / Q000378:metabolism*; D009194:Myeloma Proteins / Q000378:metabolism*; D011188:Potassium / Q000378:metabolism; D011507:Proteinuria / Q000209:etiology; D051381:Rats; D012964:Sodium / Q000378:metabolism
D007147:Immunoglobulin Light Chains; D009194:Myeloma Proteins; D000255:Adenosine Triphosphate; D001536:Bence Jones Protein; D012964:Sodium; D000251:Adenosine Triphosphatases; D011188:Potassium